Literature DB >> 2380667

Determination of L-carnitine in biological fluids and tissues.

T Deufel1.   

Abstract

In most biological materials, free L-carnitine is present together with short-chain and long-chain carnitine esters. These are differentiated mainly according to their solubility in aqueous solvents. A standardized extraction procedure is therefore essential for reproducible estimations of carnitine content. Assays of L-carnitine are based on the reaction of L-carnitine with acetyl CoA with formation of acetyl L-carnitine and free CoASH, catalysed by carnitine acetyl transferase (EC 2.3.1.7). The two main principles employed to monitor this reaction are a) measurement of the incorporation of radio-labelled acetyl groups derived from acetyl CoA into acetyl carnitine, and b) photometric determination of free CoASH formed in the reaction, using thiol-group colour reagents or an enzymatic reaction. To avoid the background due to thiol-compounds in the sample, we suggest the introduction of an oxidation step with hydrogen peroxide, which is then removed with catalase. Using this method, we have established reference ranges for total acid-soluble L-carnitine and free L-carnitine in serum (men: 44.2-79.3, and 34.8-69.5, women: 28.1-66.4 and 19.3-53.9 mumol/l, resp.), skeletal muscle (adults: 21.0-23.1, and 19.5-35.1, children: 16.1-39.0 and 12.1-25.5 mumol/g non-collagen protein, resp.), and urine. The concentration of long-chain acyl L-carnitine in serum is 2.0-4.0 mumol/l. Carnitine levels in serum, tissues and urine are age-dependent with lower levels in newborn children. The ratio of short-chain acyl carnitine to free carnitine is mainly a reflection of hepatic acetyl CoA production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380667

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  10 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Activation of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum by palmitoyl carnitine.

Authors:  R el-Hayek; C Valdivia; H H Valdivia; K Hogan; R Coronado
Journal:  Biophys J       Date:  1993-08       Impact factor: 4.033

3.  Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.

Authors:  David B Engle; Jennifer A Belisle; Jennifer A A Gubbels; Sarah E Petrie; Paul R Hutson; David M Kushner; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2009-03       Impact factor: 5.482

4.  The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease.

Authors:  M Demirkol; A C Sewell; H Böhles
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

5.  L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.

Authors:  Marcello Romano; Marco Vacante; Erika Cristaldi; Valentina Colonna; Maria Pia Gargante; Lisa Cammalleri; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

Review 6.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  L-carnitine: a partner between immune response and lipid metabolism ?

Authors:  G Famularo; S Tzantzoglou; G Santini; V Trinchieri; S Moretti; A Koverech; C De Simone
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

Review 8.  The role of carnitine in maintenance dialysis therapy.

Authors:  Heather A Morgans; Vimal Chadha; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

9.  Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.

Authors:  F Graziano; R Bisonni; V Catalano; R Silva; S Rovidati; E Mencarini; B Ferraro; F Canestrari; A M Baldelli; A De Gaetano; P Giordani; E Testa; V Lai
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

10.  Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.

Authors:  Cecilia Maldonado; Natalia Guevara; Cecilia Queijo; Raquel González; Pietro Fagiolino; Marta Vázquez
Journal:  Biomed Res Int       Date:  2016-02-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.